Analysis of blood parameters is relevant to risk evaluation as the changes in hematological system have a higher predictive value for human toxicity, when data are translated from animal studies. The results indicate that functional drink from P. crocatum and C. burmanii was not toxic to the circulating blood cells, nor interfered with their production. Hematopoiesis and leucopoiesis were also not affected even though the haematopoietic system is one of the most sensitive targets for toxic compounds and an important index of physiological and pathological status in man and animals ( Arawwawala et al. 2011). Therefore, it is possible to assume that the functional drink from P. crocatum and C. burmanii is not hematotoxic.
Glucose, triglycerides, cholesterol, SGOT and SGPT plasma level remained normal after administration of functional drink of P. crocatum and C. burmanii for 28 days. This result represents a normal liver function with no impairment ( Sateesh & Veeranjaneyulu 2009). Renal functions markers like urea and creatinine plasma levels remained normal after administration of functional drink of P. crocatum and C. burmanii at all selected dose levels. Thus it can be stated that functional drink of P. crocatum and C. burmanii does not show any renal toxicity ( Tembhurne & Sakarkar 2010). However, subacute toxicity of Alstonia congensis Engler (Apocynaceae) bark and Xylopia aethiopica (Dunal) A. Rich (Annonaceae) fruits mixtures used in the treatment of diabetes revealed a tendency to cause kidney problems on a long-term use ( Ogbannia 2008).
In conclusion, at the oral doses tested, the functional drink of P. crocatum and C. burmannii was well tolerated and neither produced overt signs of clinical toxicity nor any signs of hepato-, nephro or haematotoxicity. Thus, functional drink of P. crocatum and C. burmannii was found to be non-toxic when oral repeated dose toxicities were performed. Overall, this study provides valuable data on toxicity profile of functional drink of P. crocatum and C. burmanii that should be useful for the planning of future preclinical and clinical studies of the formulation.